I-Mab Biopharma (IMAB) Misses Q2 EPS by 3c

I-Mab Biopharma (NASDAQ: IMAB) reported Q2 EPS of ($0.07), $0.03 worse than the analyst estimate of ($0.04).

For earnings history and earnings-related data on I-Mab Biopharma (IMAB) click here.

You May Also Be Interested In

• Amer Sports Inc. (AS) PT Lowered to $42 at Truist, but 'Momentum continues to surge in a tough macro'
• Estee Lauder shares jump as fiscal 2027 profit forecast tops estimates
• Truist's 2Q26 Off-Cycle Earnings Preview for Cybersecurity Software: 'We favor RBRK and SAIL'